Gilgamesh Pharmaceuticals is a clinical-stage biotech designing next-generation psychiatric medicines, including novel psychedelic and neuroplasticity-promoting compounds, for conditions such as major depressive disorder. Its lead asset bretisilocin (GM-2505) is a rapid-acting drug with a roughly two-hour treatment window; AbbVie agreed in 2025 to acquire the program for up to $1.2 billion.
Create a free account to read all 2 signals, the milestone timeline and catalyst watch for Gilgamesh Pharmaceuticals.
Create a free accountEvery Monday: up to 5 major breakthroughs and launches, explained in plain English. Free. No account needed.
One email a week. Unsubscribe anytime.